Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Adhera Therapeutics Inc (ATRX)
USD0.00
+0.00 (+0.00%)
US OTC Healthcare Medical - Pharmaceuticals
Address
8000 Innovation Parkway 70820
Baton Rouge, LA, US
Baton Rouge, LA, US
CEO
David A. Battat
Website
adherathera.com
IPO
1993-12-07
CIK 737207 ISIN US00687E4061
Description
Adhera Therapeutics, Inc., a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs. The company is developing MLR-1019 for the treatment of Parkinson’s disease; and MLR -1023 to treat Type 1 diabetes. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.00
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
118
Beta
873.86
Float Shares
6.70M
Free Float %
92.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | -99.91% | -100.00% | -100.00% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.00
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-2,691.62
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Pharmaceuticals: +7.8%—
-
EPS growth Medical - Pharmaceuticals: +20.2%+90.8% ★ Q3'23: -45.6% (vs Q3'22)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%—
-
EBIT margin Medical - Pharmaceuticals: +6.8%—
-
ROIC Medical - Pharmaceuticals: +6.1%— Q3'23: +75.5% (vs Q3'22)
-
Share dilution Medical - Pharmaceuticals: +0.0%+255.0% Q3'23: +36.2% (vs Q3'22)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×— Q3'23: -1.02× (vs Q3'22)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2011 actual |
Dec 2012 actual |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.24M
est: 1.15M (+94.8%)
|
4.22M
est: 1.23M (+243.5%)
|
2.12M
est: 1.39M (+52.1%)
|
500.0K
est: 1.53M (-67.3%)
|
680.0K
est: 1.68M (-59.6%)
|
—
est: 1.85M (-100.0%)
|
—
est: 2.04M (-100.0%)
|
76.2K
est: 2.24M (-96.6%)
|
252.0K
est: 2.46M (-89.8%)
|
—
est: 2.71M (-100.0%)
|
—
est: 2.98M (-100.0%)
|
—
est: 3.28M (-100.0%)
|
3.61M
est.
|
| EBITDA |
-27.03M
est: -15.22M (-77.5%)
|
-7.24M
est: -16.38M (+55.8%)
|
-1.36M
est: -18.64M (+92.7%)
|
-5.47M
est: -20.50M (+73.3%)
|
3.34M
est: -22.55M (+114.8%)
|
-709.0K
est: -24.81M (+97.1%)
|
-5.64M
est: -27.29M (+79.3%)
|
-16.27M
est: -30.02M (+45.8%)
|
-11.23M
est: -33.02M (+66.0%)
|
-1.99M
est: -36.32M (+94.5%)
|
—
est: -39.96M (+100.0%)
|
—
est: -43.95M (+100.0%)
|
-48.35M
est.
|
| EBIT |
-28.28M
est: -22.10M (-28.0%)
|
-7.79M
est: -23.90M (+67.4%)
|
-1.36M
est: -27.29M (+95.0%)
|
-5.47M
est: -30.02M (+81.8%)
|
-1.11M
est: -33.03M (+96.6%)
|
-758.0K
est: -36.33M (+97.9%)
|
-6.09M
est: -39.96M (+84.8%)
|
-16.61M
est: -43.96M (+62.2%)
|
-11.32M
est: -48.35M (+76.6%)
|
-1.99M
est: -53.19M (+96.3%)
|
-674.0K
est: -58.51M (+98.8%)
|
-1.62M
est: -64.36M (+97.5%)
|
-70.80M
est.
|
| Net Income |
-29.42M
est: -16.59M (-77.4%)
|
-9.55M
est: -17.87M (+46.6%)
|
-1.57M
est: -20.35M (+92.3%)
|
-6.48M
est: -22.38M (+71.1%)
|
3.34M
est: -24.62M (+113.6%)
|
-837.0K
est: -27.08M (+96.9%)
|
-6.22M
est: -29.79M (+79.1%)
|
-16.76M
est: -32.77M (+48.9%)
|
-11.98M
est: -36.05M (+66.8%)
|
-3.77M
est: -39.66M (+90.5%)
|
-6.35M
est: -43.62M (+85.4%)
|
-2.11M
est: -47.98M (+95.6%)
|
-52.78M
est.
|
| SGA |
8.37M
est: 38.90M (-78.5%)
|
5.25M
est: 41.60M (-87.4%)
|
1.77M
est: 47.12M (-96.3%)
|
3.33M
est: 51.83M (-93.6%)
|
785.3K
est: 57.02M (-98.6%)
|
599.7K
est: 62.72M (-99.0%)
|
4.73M
est: 68.99M (-93.1%)
|
9.67M
est: 75.89M (-87.3%)
|
9.97M
est: 83.48M (-88.1%)
|
2.04M
est: 91.83M (-97.8%)
|
674.0K
est: 101.01M (-99.3%)
|
1.62M
est: 111.11M (-98.5%)
|
122.22M
est.
|
| EPS |
-929.93
est: -148.32 (-527.0%)
|
-142.30
est: -163.32 (+12.9%)
|
-18.55
est: -181.74 (+89.8%)
|
-102.00
est: -199.91 (+49.0%)
|
20.00
est: -219.90 (+109.1%)
|
-3.53
est: -241.89 (+98.5%)
|
-12.65
est: -266.09 (+95.2%)
|
-32.80
est: -292.69 (+88.8%)
|
-24.80
est: -321.96 (+92.3%)
|
-9.80
est: -354.16 (+97.2%)
|
-12.84
est: -389.57 (+96.7%)
|
-1.18
est: -428.53 (+99.7%)
|
-471.39
est.
|
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-808.2K
OE per share TTM
-0.24
Owner's Yield
-187,768.15%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
21.9%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
27
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 13G | 5.29M | 8.60% | — | 5.29M | — | 5.29M | CO | Delaware | 2011-05-27 | ↗ |
| 2 | Lynne Murphy | 5.26M | 5.90% | 5.26M | — | 5.26M | — | IN | United States | 2016-11-22 | ↗ |
| 3 | Mihir Munsif | 5.26M | 5.90% | 5.26M | — | 5.26M | — | IN | United States | 2016-11-23 | ↗ |
| 4 | Pyng Soon | 5.26M | 5.90% | 5.26M | — | 5.26M | — | IN | United States | 2016-11-23 | ↗ |
| 5 | Iroquois Capital Management LLC | 4.48M | 9.90% | — | — | — | — | OO | Delaware | 2010-01-25 | ↗ |
| 6 | Novartis AG | 2.90M | 13.12% | 2.90M | — | 2.90M | 10.00 | CO | Switzerland | 2010-08-03 | ↗ |
| 7 | Novartis Bioventures Ltd. | 2.90M | 13.12% | 2.90M | — | 2.90M | 10.00 | CO | Bermuda | 2010-08-03 | ↗ |
| 8 | Edward C. Johnson 3d | 2.89M | 11.18% | — | — | 2.89M | — | IN | United States of America | 2008-02-14 | ↗ |
| 9 | FMR Corp. | 2.71M | 12.32% | — | — | 2.71M | — | HC | Delaware | 2007-02-14 | ↗ |
| 10 | BioMed Realty Trust, Inc. | 2.12M | 6.20% | — | — | — | 2.12M | CO | Maryland | 2011-02-28 | ↗ |
| 11 | BioMed Realty, L.P. | 2.12M | 6.20% | — | — | — | 2.12M | PN | Maryland | 2011-02-28 | ↗ |
| 12 | Martin D. Hoe | 1.60M | 6.04% | — | 1.60M | — | — | IN | United States | 2011-02-11 | ↗ |
| 13 | Ryan M. Lane | 1.60M | 6.04% | — | 1.60M | — | — | IN | United States | 2011-02-11 | ↗ |
| 14 | Great Point Partners, LLC | 1.54M | 6.99% | — | 15.44M | — | 15.44M | OO | USA | 2010-08-02 | ↗ |
| 15 | Socius CG II, Ltd. | 1.31M | 9.90% | 1.31M | — | 1.31M | — | OO | Bermuda | 2011-12-30 | ↗ |
| 16 | Socius Capital Group, LLC | 1.31M | 9.90% | 1.31M | — | 1.31M | — | HC | Bermuda | 2011-12-30 | ↗ |
| 17 | Terren S. Peizer | 1.31M | 9.90% | 1.31M | — | 1.31M | — | IN | Bermuda | 2011-12-30 | ↗ |
| 18 | Pryor Cashman LLP | 1.26M | 4.90% | 1.26M | — | 1.26M | — | PN | State of New York | 2014-07-29 | ↗ |
| 19 | No. of Above Person | 1.08M | 16.90% | — | 1.08M | — | 1.08M | IA | State of Washington | 1999-02-12 | ↗ |
| 20 | Empery Asset Management, LP | 740.0K | 4.99% | — | 49.5K | — | 49.5K | PN | Delaware | 2012-01-26 | ↗ |
| 21 | 2 | 555.0K | 2.20% | — | 555.0K | — | 555.0K | CO | United States | 2015-02-10 | ↗ |
| 22 | 11-3485705 | 514.2K | 2.80% | — | 511.4K | — | 511.4K | OO | Delaware | 2005-02-14 | ↗ |
| 23 | 13-3532932 | 514.2K | 2.80% | — | 2.8K | — | 2.8K | BD, PN | Delaware | 2005-02-14 | ↗ |
| 24 | Israel A. Englander | 514.2K | 2.80% | — | 514.2K | — | 514.2K | IN | United States | 2005-02-14 | ↗ |
| 25 | Joseph Edelman | 411.5K | 4.49% | 411.5K | — | 411.5K | — | IN | United States | 2002-01-23 | ↗ |
| 26 | Capital Ventures International | — | 0.00% | — | — | — | — | CO | Cayman Islands | 2012-02-14 | ↗ |
| 27 | Heights Capital Management, Inc. | — | 0.00% | — | — | — | — | CO | Delaware | 2012-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
0
Sells
0
Shares acquired
—
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+0
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-11-05 | Subhan Zahed | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-04-20 | Waerness Trond Kydd | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-07-07 | KUCHARCHUK ANDREW ALBERT | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-11-01 | Stanley Rhonda L. | Officer | A-Award | A | Options to purchase common stock | 350,000 | 0.09 | 31.5K | 350,000 | — | ↗ |
| 2019-04-04 | Phelan Nancy R. | Director / Officer | A-Award | A | Options to purchase common stock | 1,500,000 | 0.37 | 555.0K | 1,500,000 | — | ↗ |
| 2019-01-15 | Teague Robert Eric | Officer | A-Award | A | Options to purchase common stock | 100,000 | 0.32 | 32.0K | 100,000 | — | ↗ |
| 2018-10-01 | Trieu Vuong | Director / 10% Owner | D-Return | D | Common Stock | 500,000 | 0.50 | 250.0K | 612,716 | — | ↗ |
| 2018-10-01 | Phelan Nancy R. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-09-24 | Teague Robert Eric | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-07-12 | Moscato Robert Jr. | Director / Officer | P-Purchase | A | Warrants to Purchase Common Stock | 300,000 | 0.55 | 165.0K | 300,000 | — | ↗ |
| 2018-07-10 | Moscato Robert Jr. | Director / Officer | A-Award | A | Options to purchase common stock | 1,500,000 | 0.66 | 990.0K | 1,500,000 | — | ↗ |
| 2018-07-10 | Hacksell Uli | Director | A-Award | A | Options to purchase common stock | 1,000,000 | 0.66 | 660.0K | 1,000,000 | — | ↗ |
| 2018-07-10 | Emerson Erik | Director / Officer | A-Award | A | Options to purchase common stock | 1,125,000 | 0.66 | 742.5K | 1,125,000 | — | ↗ |
| 2018-07-01 | Hacksell Uli | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-06-18 | Moscato Robert Jr. | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-05-02 | Ranker Philip C | — | A-Award | A | Options to purchase common stock | 200,000 | 0.98 | 196.0K | 200,000 | — | ↗ |
| 2018-05-02 | Ramelli Joseph W. | — | A-Award | A | Options to purchase common stock | 100,000 | 0.98 | 98.0K | 100,000 | — | ↗ |
| 2018-05-02 | Calais Philippe | — | A-Award | A | Options to purchase common stock | 80,000 | 0.98 | 78.4K | 80,000 | — | ↗ |
| 2018-04-27 | Boris Timothy | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-04-16 | Williams Donald Allen | Director | A-Award | A | Warrants to Purchase Common Stock | 135,000 | 0.55 | 74.3K | 135,000 | — | ↗ |
| 2018-04-16 | Trieu Vuong | Director / Officer / 10% Owner | C-Conversion | D | 5% Demand Line of Credit | 0 | 5,000.00 | — | 0 | — | ↗ |
| 2018-04-16 | Hwang Larn | Officer | C-Conversion | D | 5% Convertible Promissory Note | 0 | 5,000.00 | — | 0 | — | ↗ |
| 2018-04-16 | BLECH ISAAC | Director | C-Conversion | D | Convertible Promissory Note | 0 | 5,000.00 | — | 0 | — | ↗ |
| 2018-01-03 | Williams Donald Allen | Director | A-Award | A | Options to purchase common stock | 3,800 | 1.56 | 5.9K | 3,800 | — | ↗ |
| 2018-01-03 | Trieu Vuong | Director / Officer / 10% Owner | A-Award | A | Options to purchase common stock | 3,800 | 1.56 | 5.9K | 3,800 | — | ↗ |
| 2018-01-03 | Ranker Philip C | Director | A-Award | A | Options to purchase common stock | 3,800 | 1.56 | 5.9K | 3,800 | — | ↗ |
| 2018-01-03 | Calais Philippe | Director | A-Award | A | Options to purchase common stock | 3,800 | 1.56 | 5.9K | 3,800 | — | ↗ |
| 2018-01-03 | BLECH ISAAC | Director | A-Award | A | Options to purchase common stock | 3,800 | 1.56 | 5.9K | 3,800 | — | ↗ |
| 2017-11-22 | BLECH ISAAC | Director | — | I | $500,000 Convertible Promissory Note Due March 2018 | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-10-12 | Weinstein Peter D. | Officer | A-Award | A | Options to purchase common stock | 60,000 | 2.40 | 144.0K | 60,000 | — | ↗ |
| 2017-10-02 | Shah Amit B. | Officer | A-Award | A | Options to purchase common stock | 60,000 | 2.70 | 162.0K | 60,000 | — | ↗ |
| 2017-06-30 | Trieu Vuong | Director / Officer / 10% Owner | A-Award | A | 5% Convertible Promissory Note | 0 | 0.35 | — | 473,240 | — | ↗ |
| 2017-06-30 | Hwang Larn | Officer | A-Award | A | 5% Convertible Promissory Note | 0 | 0.35 | — | 142,857 | — | ↗ |
| 2017-06-22 | Emerson Erik | Officer | — | D | Common Stock | 0 | 0.00 | — | 600,000 | — | ↗ |
| 2017-06-09 | Trieu Vuong | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 10,000 | 0.39 | 3.9K | 11,127,141 | — | ↗ |
| 2017-04-07 | Ramelli Joseph W. | Officer | P-Purchase | A | Common Stock | 22,500 | 0.43 | 9.6K | 440,653 | — | ↗ |
| 2017-04-06 | Ramelli Joseph W. | Officer | P-Purchase | A | Common Stock | 13,000 | 0.34 | 4.4K | 418,153 | — | ↗ |
| 2017-04-05 | Ramelli Joseph W. | Officer | P-Purchase | A | Common Stock | 97,550 | 0.31 | 30.4K | 405,153 | — | ↗ |
| 2017-02-13 | Munsif Mihir | Officer | A-Award | A | Options to purchase common stock | 60,000 | 0.18 | 10.8K | 60,000 | — | ↗ |
| 2017-02-13 | Hwang Larn | Officer | A-Award | A | Options to purchase common stock | 60,000 | 0.18 | 10.8K | 60,000 | — | ↗ |
| 2017-02-10 | Munsif Mihir | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-02-06 | Trieu Vuong | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 862,068 | 0.29 | 250.0K | 862,068 | — | ↗ |
| 2017-02-02 | Ramelli Joseph W. | Officer | A-Award | A | Common Stock | 100,000 | 0.00 | — | 307,603 | — | ↗ |
| 2017-01-03 | Williams Donald Allen | Director | A-Award | A | Options to purchase common stock | 81,000 | 0.17 | 13.8K | 81,000 | — | ↗ |
| 2017-01-03 | Trieu Vuong | Director / Officer / 10% Owner | A-Award | A | Options to purchase common stock | 81,000 | 0.17 | 13.8K | 81,000 | — | ↗ |
| 2017-01-03 | Ranker Philip C | Director | A-Award | A | Options to purchase common stock | 81,000 | 0.17 | 13.8K | 81,000 | — | ↗ |
| 2017-01-03 | Ramelli Joseph W. | Officer | A-Award | A | Options to purchase common stock | 81,000 | 0.17 | 13.8K | 81,000 | — | ↗ |
| 2017-01-03 | Loren Stefan | Director | A-Award | A | Options to purchase common stock | 81,000 | 0.17 | 13.8K | 81,000 | — | ↗ |
| 2017-01-03 | Calais Philippe | Director | A-Award | A | Options to purchase common stock | 81,000 | 0.17 | 13.8K | 81,000 | — | ↗ |
| 2016-11-15 | Williams Donald Allen | Director | A-Award | A | Options to purchase common stock | 35,000 | 0.10 | 3.5K | 35,000 | — | ↗ |
| 2016-11-15 | Trieu Vuong | Director / Officer / 10% Owner | A-Award | A | Common Stock | 23,123,558 | 0.00 | — | 23,123,558 | — | ↗ |
| 2016-11-15 | Ranker Philip C | Director | A-Award | A | Options to purchase common stock | 35,000 | 0.10 | 3.5K | 35,000 | — | ↗ |
| 2016-11-15 | Ramelli Joseph W. | Director / Officer | A-Award | A | Options to purchase common stock | 35,000 | 0.10 | 3.5K | 35,000 | — | ↗ |
| 2016-11-15 | Loren Stefan | Director | A-Award | A | Options to purchase common stock | 35,000 | 0.10 | 3.5K | 35,000 | — | ↗ |
| 2016-11-15 | Autotelic LLC | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 23,123,558 | — | ↗ |
| 2016-01-04 | Williams Donald Allen | Director | A-Award | A | Options to purchase common stock | 38,000 | 0.26 | 9.9K | 38,000 | — | ↗ |
| 2016-01-04 | Ranker Philip C | Director | A-Award | A | Options to purchase common stock | 38,000 | 0.26 | 9.9K | 38,000 | — | ↗ |
| 2016-01-04 | Ramelli Joseph W. | Director | A-Award | A | Options to purchase common stock | 38,000 | 0.26 | 9.9K | 38,000 | — | ↗ |
| 2016-01-04 | Loren Stefan | Director | A-Award | A | Options to purchase common stock | 38,000 | 0.26 | 9.9K | 38,000 | — | ↗ |
| 2015-01-06 | Williams Donald Allen | Director | A-Award | A | Options to purchase common stock | 38,000 | 0.64 | 24.1K | 38,000 | — | ↗ |
| 2015-01-06 | Ranker Philip C | Director | A-Award | A | Options to purchase common stock | 38,000 | 0.64 | 24.1K | 38,000 | — | ↗ |
| 2015-01-06 | Ramelli Joseph W. | Director | A-Award | A | Options to purchase common stock | 38,000 | 0.64 | 24.1K | 38,000 | — | ↗ |
| 2015-01-06 | Loren Stefan | Director | A-Award | A | Options to purchase common stock | 38,000 | 0.64 | 24.1K | 38,000 | — | ↗ |
| 2014-12-30 | FRENCH J MICHAEL | Director / Officer | F-InKind | D | Common Stock | 309,055 | 0.33 | 102.0K | 822,283 | — | ↗ |
| 2014-09-15 | Williams Donald Allen | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2014-09-15 | Ranker Philip C | Director | A-Award | A | Options to purchase common stock | 62,000 | 1.07 | 66.3K | 62,000 | — | ↗ |
| 2014-09-15 | Ramelli Joseph W. | Director | A-Award | A | Options to purchase common stock | 62,000 | 1.07 | 66.3K | 62,000 | — | ↗ |
| 2014-09-15 | Loren Stefan | Director | A-Award | A | Options to purchase common stock | 62,000 | 1.07 | 66.3K | 62,000 | — | ↗ |
| 2014-09-15 | FRENCH J MICHAEL | Director / Officer | A-Award | A | Options to purchase common stock | 771,000 | 1.07 | 825.0K | 771,000 | — | ↗ |
| 2014-02-10 | Pryor Cashman LLP | 10% Owner | S-Sale | D | common stock, par value $0.006 per share | 15,000 | 1.02 | 15.3K | 1,591,959 | — | ↗ |
| 2014-02-07 | Pryor Cashman LLP | 10% Owner | S-Sale | D | common stock, par value $0.006 per share | 59,000 | 1.01 | 59.4K | 1,606,959 | — | ↗ |
| 2014-02-06 | Pryor Cashman LLP | 10% Owner | S-Sale | D | common stock, par value $0.006 per share | 34,041 | 0.95 | 32.3K | 1,665,959 | — | ↗ |
| 2014-01-09 | Geffken Daniel E. | Officer | — | I | warrant to purchase shares of common stock | 100,800 | 0.48 | 48.5K | 0 | — | ↗ |
| 2014-01-01 | Ranker Philip C | Director / Officer | A-Award | A | Common Stock | 897,303 | 318,000.00 | 285.34B | 897,553 | — | ↗ |
| 2014-01-01 | Ramelli Joseph W. | Director | A-Award | A | Common Stock | 181,303 | 0.33 | 59.8K | 181,303 | — | ↗ |
| 2014-01-01 | Loren Stefan | Director | A-Award | A | Common Stock | 181,303 | 0.33 | 59.8K | 181,303 | — | ↗ |
| 2014-01-01 | Ho Richard Theodore | Officer | A-Award | A | Common Stock | 390,000 | 516,000.00 | 201.24B | 390,000 | — | ↗ |
| 2014-01-01 | FRENCH J MICHAEL | Director / Officer | A-Award | A | Common Stock | 1,131,000 | 415,000.00 | 469.37B | 1,132,338 | — | ↗ |
| 2013-10-04 | Pryor Cashman LLP | 10% Owner | S-Sale | D | common stock, par value $0.006 per share | 35,000 | 0.24 | 8.3K | 1,700,000 | — | ↗ |
| 2013-10-03 | Pryor Cashman LLP | 10% Owner | S-Sale | D | common stock, par value $0.006 per share | 65,000 | 0.25 | 16.3K | 1,735,000 | — | ↗ |
| 2012-08-21 | Pryor Cashman LLP | 10% Owner | — | D | Common Stock, par value $0.006 per share | 0 | 0.00 | — | 1,800,000 | — | ↗ |
| 2012-08-20 | Ramelli Joseph W. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2011-09-27 | BioMed Realty Trust Inc | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 9,915,727 | — | ↗ |
| 2011-09-07 | Ranker Philip C | Officer | A-Award | A | Marina Biotech, Inc. Common Stock Options | 25,000 | 0.22 | 5.5K | 25,000 | — | ↗ |
| 2011-09-02 | Taylor Michael Douglas | Director | A-Award | A | Marina Biotech, Inc. Common Stock Options | 75,000 | 0.21 | 15.8K | 75,000 | — | ↗ |
| 2011-09-02 | SESSLER GREGORY | Director | A-Award | A | Marina Biotech, Inc. Common Stock Options | 75,000 | 0.21 | 15.8K | 75,000 | — | ↗ |
| 2011-09-02 | Parker Peter | Director | A-Award | A | Marina Biotech, Inc. Common Stock Options | 75,000 | 0.21 | 15.8K | 75,000 | — | ↗ |
| 2011-09-02 | Karis James | Director | A-Award | A | Marina Biotech, Inc. Common Stock Options | 100,000 | 0.21 | 21.0K | 100,000 | — | ↗ |
| 2011-09-02 | Ho Richard Theodore | Officer | A-Award | A | Marina Biotech, Inc. Common Stock Options | 300,000 | 0.21 | 63.0K | 300,000 | — | ↗ |
| 2011-09-02 | FLETCHER R JOHN | Director | A-Award | A | Marina Biotech, Inc. Common Stock Options | 75,000 | 0.21 | 15.8K | 75,000 | — | ↗ |
| 2011-08-26 | POLISKY BARRY | Officer | A-Award | A | Marina Biotech, Inc. Common Stock Options | 115,000 | 0.20 | 23.0K | 115,000 | — | ↗ |
| 2011-08-26 | GARCIA PETER S | Officer | A-Award | A | Marina Biotech, Inc. Common Stock Options | 107,500 | 0.20 | 21.5K | 107,500 | — | ↗ |
| 2011-08-26 | FRENCH J MICHAEL | Director / Officer | A-Award | A | Marina Biotech, Inc. Common Stock Options | 435,000 | 0.20 | 87.0K | 435,000 | — | ↗ |
| 2011-08-16 | Parker Peter | Director | J-Other | D | Marina Biotech, Inc. Common Stock | 40,200 | 0.24 | 9.6K | 84,010 | — | ↗ |
| 2011-07-14 | FLETCHER R JOHN | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2011-04-14 | SESSLER GREGORY | Director | A-Award | A | Marina Biotech, Inc. Common Stock Option | 3,594 | 0.55 | 2.0K | 3,594 | — | ↗ |
| 2011-04-14 | Parker Peter | Director | A-Award | A | Marina Biotech, Inc. Common Stock Option | 3,594 | 0.55 | 2.0K | 3,594 | — | ↗ |
| 2011-03-31 | GARCIA PETER S | Officer | J-Other | A | Marina Biotech Common Stock | 5,000 | 0.60 | 3.0K | 5,000 | — | ↗ |
| 2011-03-31 | FRENCH J MICHAEL | Director / Officer | J-Other | A | Marina Biotech Common Stock | 5,000 | 0.60 | 3.0K | 8,375 | — | ↗ |
| 2011-02-11 | Parker Peter | Director | J-Other | A | Common Stock | 116,253 | 0.00 | — | 124,210 | — | ↗ |
| 2011-01-26 | Novartis Bioventures Ltd | 10% Owner | S-Sale | D | Common Stock | 10,730 | 1.19 | 12.8K | 2,500,901 | — | ↗ |
| 2011-01-25 | Novartis Bioventures Ltd | 10% Owner | S-Sale | D | Common Stock | 700 | 1.20 | 840.00 | 2,569,565 | — | ↗ |
| 2011-01-24 | Novartis Bioventures Ltd | 10% Owner | S-Sale | D | Common Stock | 3,883 | 1.19 | 4.6K | 2,711,887 | — | ↗ |
| 2011-01-21 | Novartis Bioventures Ltd | 10% Owner | S-Sale | D | Common Stock | 5,935 | 1.27 | 7.5K | 2,736,770 | — | ↗ |
| 2011-01-20 | Novartis Bioventures Ltd | 10% Owner | S-Sale | D | Common Stock | 1,943 | 1.32 | 2.6K | 2,840,227 | — | ↗ |
| 2011-01-19 | Novartis Bioventures Ltd | 10% Owner | S-Sale | D | Common Stock | 6,400 | 1.52 | 9.7K | 2,878,870 | — | ↗ |
| 2010-10-14 | GARCIA PETER S | Officer | A-Award | A | Marina Biotech, Inc. Common Stock Options | 22,500 | 2.45 | 55.1K | 22,500 | — | ↗ |
| 2010-10-14 | FRENCH J MICHAEL | Director / Officer | A-Award | A | Marina Biotech, Inc. Common Stock Options | 79,700 | 2.45 | 195.3K | 79,700 | — | ↗ |
| 2010-07-21 | Taylor Michael Douglas | Director | — | D | Marina Biotech Stock Options | 6,378 | 1.25 | 8.0K | 0 | — | ↗ |
| 2010-07-21 | SESSLER GREGORY | Director | A-Award | A | Marina Biotech, Inc. Common Stock Option | 12,938 | 2.98 | 38.6K | 12,938 | — | ↗ |
| 2010-07-21 | Parker Peter | Director | — | D | Marina Biotech Stock Options | 48,120 | 3.24 | 155.9K | 0 | — | ↗ |
| 2010-07-21 | Novartis Bioventures Ltd | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 2,899,070 | — | ↗ |
| 2010-07-21 | LI CHIANG J | Director | A-Award | A | Marina Biotech, Inc. Common Stock Option | 11,500 | 2.98 | 34.3K | 11,500 | — | ↗ |
| 2010-07-21 | Karis James | Director | A-Award | A | Marina Biotech, Inc. Common Stock Option | 11,500 | 2.98 | 34.3K | 11,500 | — | ↗ |
| 2009-12-23 | Loren Stefan | Director | — | D | Warrants to purchase common stock | 4,032 | 18.40 | 74.2K | 0 | — | ↗ |
| 2009-09-30 | FRENCH J MICHAEL | Director / Officer | J-Other | A | Marina Biotech Common Stock | 875 | 4.76 | 4.2K | 3,375 | — | ↗ |
| 2009-08-11 | Karis James | Director | A-Award | A | MDRNA, Inc. Common Stock Option | 34,500 | 1.53 | 52.8K | 34,500 | — | ↗ |
| 2009-07-13 | GARCIA PETER S | Officer | A-Award | A | MDRNA, Inc. Common Stock Option | 120,000 | 3.39 | 406.8K | 120,000 | — | ↗ |
| 2009-05-20 | YORK BRUCE R | Officer | A-Award | A | MDRNA, Inc. Common Stock Option | 120,000 | 1.52 | 182.4K | 120,000 | — | ↗ |
| 2009-05-20 | THAW BRUCE R/FA | Director | A-Award | A | MDRNA, Inc. Common Stock Option | 74,750 | 1.52 | 113.6K | 74,750 | — | ↗ |
| 2009-05-20 | SESSLER GREGORY | Director | A-Award | A | MDRNA, Inc. Common Stock Option | 51,750 | 1.52 | 78.7K | 51,750 | — | ↗ |
| 2009-05-20 | Rothman James | Director | A-Award | A | MDRNA, Inc. Common Stock Option | 46,000 | 1.52 | 69.9K | 46,000 | — | ↗ |
| 2009-05-20 | POLISKY BARRY | Officer | A-Award | A | MDRNA, Inc. Common Stock Option | 120,000 | 1.52 | 182.4K | 120,000 | — | ↗ |
| 2009-05-20 | PETERS DANIEL | Director | A-Award | A | MDRNA, Inc. Common Stock Option | 46,000 | 1.52 | 69.9K | 46,000 | — | ↗ |
| 2009-05-20 | FRENCH J MICHAEL | Officer | A-Award | A | MDRNA, Inc. Common Stock Option | 240,000 | 1.52 | 364.8K | 240,000 | — | ↗ |
| 2009-03-20 | QUAY STEVEN C | Director | A-Award | A | Common Stock of MDRNA, Inc. | 731,275 | 0.00 | — | 1,166,504 | — | ↗ |
| 2009-03-16 | QUAY STEVEN C | Director | J-Other | D | Common Stock Options of MDRNA, Inc. | 800,000 | 12.94 | 10.35M | 1,704,247 | — | ↗ |
| 2009-01-02 | POLISKY BARRY | Officer | A-Award | A | MDRNA, Inc. Common Stock Option | 120,000 | 2.35 | 282.0K | 360,000 | — | ↗ |
| 2008-10-28 | QUAY STEVEN C | Director | J-Other | D | Common Stock Options of MDRNA, Inc. | 100,000 | 25.00 | 2.50M | 2,504,247 | — | ↗ |
| 2008-08-11 | FRENCH J MICHAEL | Officer | P-Purchase | A | MDRNA, Inc. Common Stock | 200 | 0.75 | 149.90 | 10,000 | — | ↗ |
| 2008-08-02 | Costantino Henry R | Officer | F-InKind | D | MDRNA, Inc. Common Stock | 438 | 1.11 | 486.18 | 24,047 | — | ↗ |
| 2008-07-14 | Costantino Henry R | Officer | S-Sale | D | MDRNA, Inc. Common Stock | 231 | 1.01 | 233.31 | 24,485 | — | ↗ |
| 2008-07-02 | Costantino Henry R | Officer | S-Sale | D | MDRNA, Inc. Common Stock | 240 | 1.17 | 280.80 | 24,716 | — | ↗ |
| 2008-07-01 | Costantino Henry R | Officer | S-Sale | D | MDRNA, Inc. Common Stock | 81 | 1.19 | 96.39 | 24,956 | — | ↗ |
| 2008-06-23 | FRENCH J MICHAEL | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2008-06-10 | YORK BRUCE R | Officer | A-Award | A | MDRNA, Inc. Common Stock Options | 120,000 | 1.19 | 142.8K | 149,000 | — | ↗ |
| 2008-06-10 | THAW BRUCE R/FA | Director | A-Award | A | MDRNA, Inc. Common Stock Options | 70,000 | 1.19 | 83.3K | 176,000 | — | ↗ |
| 2008-06-10 | SESSLER GREGORY | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2008-06-10 | Rothman James | Director | A-Award | A | MDRNA, Inc. Common Stock Options | 45,000 | 1.19 | 53.6K | 45,000 | — | ↗ |
| 2008-06-10 | QUAY STEVEN C | Director / Officer | A-Award | A | MDRNA, Inc. Common Stock Options | 420,000 | 1.19 | 499.8K | 1,924,247 | — | ↗ |
| 2008-06-10 | POLLOCK JOHN V | Director | A-Award | A | MDRNA, Inc. Common Stock Options | 55,000 | 1.19 | 65.5K | 137,500 | — | ↗ |
| 2008-06-10 | PETERS DANIEL | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2008-06-10 | CROSS ALEXANDER D | Director | A-Award | A | MDRNA, Inc Common Stock Options | 45,000 | 1.19 | 53.6K | 83,000 | — | ↗ |
| 2008-06-10 | BAYH SUSAN B | Director | A-Award | A | MDRNA, Inc Common Stock Options | 55,000 | 1.19 | 65.5K | 87,500 | — | ↗ |
| 2008-05-14 | CROSS ALEXANDER D | Director | A-Award | A | Nastech Pharmaceutical Company Inc Common Stock | 10,000 | 1.26 | 12.6K | 38,000 | — | ↗ |
| 2008-05-13 | THAW BRUCE R/FA | Director | P-Purchase | A | Nastech Pharmaceutical Company Common Stock | 36,602 | 1.15 | 42.1K | 159,155 | — | ↗ |
| 2008-05-12 | Stanewick Gerald T | Director | P-Purchase | A | Nastech Pharmaceutical Company Inc Common Stock | 10,000 | 1.14 | 11.4K | 116,412 | — | ↗ |
| 2008-04-01 | QUAY STEVEN C | Director / Officer | J-Other | A | Nastech Pharmaceutical Company Inc Common Stock | 3,500 | 2.00 | 7.0K | 434,459 | — | ↗ |
| 2008-04-01 | BRANDT GORDON | Officer | J-Other | A | Nastech Pharmaceutical Company Inc Common Stock | 1,201 | 2.00 | 2.4K | 41,705 | — | ↗ |
| 2008-02-12 | YORK BRUCE R | Officer | A-Award | D | Nastech Pharmaceutical Company Inc Common Stock | 14,400 | 0.00 | — | 35,232 | — | ↗ |
| 2008-02-12 | Duffy Timothy M | Officer | A-Award | A | Nastech Pharmaceutical Company Inc. Common Stock Options | 35,000 | 2.22 | 77.7K | 87,984 | — | ↗ |
| 2007-12-19 | BRANDT GORDON | Officer | A-Award | A | Nastech Pharmaceutical Company Inc Common Stock | 18,000 | 0.00 | — | 40,504 | — | ↗ |
| 2007-12-17 | BRANDT GORDON | Officer | F-InKind | D | Nastech Pharmaceutical Company Inc Common Stock | 661 | 3.60 | 2.4K | 22,504 | — | ↗ |
| 2007-12-07 | YORK BRUCE R | Officer | P-Purchase | A | Nastech Pharmaceutical Company Inc Common Stock | 2,000 | 4.04 | 8.1K | 20,832 | — | ↗ |
| 2007-11-01 | WENIG DEVIN | Director | S-Sale | D | Nastech Pharmaceutical Company Inc Common Stock | 1,000 | 14.20 | 14.2K | 307,287 | — | ↗ |
| 2007-10-09 | WENIG DEVIN | Director | S-Sale | D | Nastech Pharmaceutical Company Inc Common Stock | 500 | 16.05 | 8.0K | 308,287 | — | ↗ |
| 2007-10-05 | JOHNSON PAUL H | Officer | F-InKind | D | Nastech Pharmaceutical Company Inc Common Stock | 660 | 15.23 | 10.1K | 29,301 | — | ↗ |
| 2007-10-04 | Costantino Henry R | Officer | — | D | Nastech Pharmaceutical Company Inc Stock Options | 6,666 | 10.24 | 68.3K | 0 | — | ↗ |
| 2007-10-01 | WENIG DEVIN | Director | S-Sale | D | Nastech Pharmaceutical Company Inc Common Stock | 400 | 13.75 | 5.5K | 310,187 | — | ↗ |
| 2007-09-27 | QUAY STEVEN C | Director / Officer | S-Sale | D | Nastech Pharmaceutical Company Inc Common Stock | 2,000 | 13.81 | 27.6K | 434,159 | — | ↗ |
| 2007-09-07 | YORK BRUCE R | Officer | F-InKind | D | Nastech Pharmaceutical Company Inc Common Stock | 53 | 14.05 | 744.65 | 18,832 | — | ↗ |
| 2007-09-07 | Ranker Philip C | Officer | F-InKind | D | Nastech Pharmaceutical Company Inc Common Stock | 69 | 14.05 | 969.45 | 46,312 | — | ↗ |
| 2007-09-06 | JOHNSON PAUL H | Officer | M-Exempt | A | Nastech Pharmaceutical Company Inc Common Stock | 54,649 | 9.36 | 511.5K | 74,494 | — | ↗ |
| 2007-09-04 | WENIG DEVIN | Director | S-Sale | D | Nastech Pharmaceutical Company Inc Common Stock | 200 | 14.00 | 2.8K | 312,987 | — | ↗ |
| 2007-08-27 | Ranker Philip C | Officer | F-InKind | D | Nastech Pharmaceutical Company Inc Common Stock | 1,321 | 14.02 | 18.5K | 46,381 | — | ↗ |
| 2007-08-23 | JOHNSON PAUL H | Officer | X-InTheMoney | D | Nastech Pharmaceutical Company Inc Stock Options | 1,339 | 9.36 | 12.5K | 66,149 | — | ↗ |
| 2007-08-22 | JOHNSON PAUL H | Officer | S-Sale | D | Nastech Pharmaceutical Company Inc Common Stock | 20,558 | 14.30 | 294.0K | 19,606 | — | ↗ |
| 2007-08-21 | JOHNSON PAUL H | Officer | M-Exempt | A | Nastech Pharmaceutical Company Inc Common Stock | 5,954 | 9.36 | 55.7K | 16,006 | — | ↗ |
| 2007-08-15 | HOLUBIAK MYRON Z | Director | S-Sale | D | Nastech Pharmaceutical Company Inc Common Stock | 3,000 | 14.19 | 42.6K | 26,657 | — | ↗ |
| 2007-08-08 | WENIG DEVIN | Director | S-Sale | D | Nastech Pharmaceutical Company Inc Common Stock | 1,100 | 16.01 | 17.6K | 315,787 | — | ↗ |
| 2007-08-01 | WENIG DEVIN | Director | S-Sale | D | Nastech Pharmaceutical Company Inc Common Stock | 131 | 12.67 | 1.7K | 320,256 | — | ↗ |
| 2007-07-25 | QUAY STEVEN C | Director / Officer | S-Sale | D | Nastech Pharmaceutical Company Inc Common Stock | 2,000 | 12.11 | 24.2K | 439,959 | — | ↗ |
| 2007-07-20 | QUAY STEVEN C | Director / Officer | F-InKind | D | Nastech Pharmaceutical Company Inc Common Stock | 11,103 | 12.61 | 140.0K | 441,959 | — | ↗ |
| 2007-07-16 | YORK BRUCE R | Officer | F-InKind | D | Nastech Pharmaceutical Company Inc Common Stock | 272 | 11.89 | 3.2K | 19,766 | — | ↗ |
| 2007-07-10 | WENIG DEVIN | Director | S-Sale | D | Nastech Pharmaceutical Company Inc Common Stock | 800 | 12.01 | 9.6K | 322,987 | — | ↗ |
| 2007-07-02 | YORK BRUCE R | Officer | F-InKind | D | Nastech Pharmaceutical Company Inc Common Stock | 101 | 10.98 | 1.1K | 15,859 | — | ↗ |
| 2007-07-02 | WENIG DEVIN | Director | S-Sale | D | Nastech Pharmaceutical Company Inc Common Stock | 200 | 11.06 | 2.2K | 324,287 | — | ↗ |
| 2007-07-02 | Ranker Philip C | Officer | F-InKind | D | Nastech Pharmaceutical Company Inc Common Stock | 192 | 10.98 | 2.1K | 47,702 | — | ↗ |
| 2007-07-02 | Duffy Timothy M | Officer | F-InKind | D | Nastech Pharmaceutical Company Inc. Common Stock | 201 | 10.98 | 2.2K | 42,195 | — | ↗ |
| 2007-06-13 | WENIG DEVIN | Director | A-Award | A | Nastech Pharmaceutical Company Inc Common Stock | 2,000 | 0.00 | — | 325,287 | — | ↗ |
| 2007-06-13 | THAW BRUCE R/FA | Director | A-Award | A | Nastech Pharmaceutical Company Inc Common Stock | 5,000 | 0.00 | — | 114,041 | — | ↗ |
| 2007-06-13 | Stanewick Gerald T | Director | A-Award | A | Nastech Pharmaceutical Company Inc Stock Options | 4,000 | 11.60 | 46.4K | 26,000 | — | ↗ |
| 2007-06-13 | POLLOCK JOHN V | Director | A-Award | A | Nastech Pharmaceutical Common Stock Options | 10,000 | 11.60 | 116.0K | 82,500 | — | ↗ |
| 2007-06-13 | MICHELSON LESLIE D | Director | A-Award | A | Nastech Pharmaceutical Company Common Stock Options | 13,000 | 11.60 | 150.8K | 43,500 | — | ↗ |
| 2007-06-13 | HOLUBIAK MYRON Z | Director | A-Award | A | Nastech Pharmaceutical Company Inc Stock Options | 9,500 | 11.60 | 110.2K | 37,000 | — | ↗ |
| 2007-06-13 | FERRIER IAN R | Director | A-Award | A | Nastech Pharmaceutical Company Inc Common Stock | 3,422 | 0.00 | — | 12,657 | — | ↗ |
| 2007-06-13 | CROSS ALEXANDER D | Director | A-Award | A | Nastech Pharmaceutical Company Inc Common Stock | 5,500 | 0.00 | — | 28,000 | — | ↗ |
| 2007-06-13 | BAYH SUSAN B | Director | A-Award | A | Nastech Pharmaceutical Company Inc Stock Options | 9,500 | 11.60 | 110.2K | 32,500 | — | ↗ |
| 2007-06-09 | Duffy Timothy M | Officer | F-InKind | D | Nastech Pharmaceutical Company Inc. Common Stock | 1,322 | 11.77 | 15.6K | 42,396 | — | ↗ |
| 2007-06-07 | QUAY STEVEN C | Director / Officer | S-Sale | D | Nastech Pharmaceutical Company Inc Common Stock | 400 | 10.95 | 4.4K | 453,062 | — | ↗ |
| 2007-06-01 | WENIG DEVIN | Director | S-Sale | D | Nastech Pharmaceutical Company Inc Common Stock | 500 | 12.05 | 6.0K | 325,787 | — | ↗ |
| 2007-05-25 | WORMUTH DAVID E | Officer | F-InKind | D | Nastech Pharmaceutical Company Inc Common Stock | 661 | 11.76 | 7.8K | 23,839 | — | ↗ |
| 2007-05-07 | WENIG DEVIN | Director | S-Sale | D | Nastech Pharmaceutical Company Inc Common Stock | 400 | 13.64 | 5.5K | 326,987 | — | ↗ |
| 2007-04-20 | BRANDT GORDON | Officer | X-InTheMoney | D | Nastech Pharmaceutical Company Inc Stock Options | 5,000 | 10.99 | 55.0K | 93,699 | — | ↗ |
| 2007-04-18 | QUAY STEVEN C | Director / Officer | S-Sale | D | Nastech Pharmaceutical Company Inc Common Stock | 2,000 | 12.00 | 24.0K | 463,312 | — | ↗ |
| 2007-04-02 | WENIG DEVIN | Director | S-Sale | D | Nastech Pharmaceutical Company Inc Common Stock | 200 | 10.83 | 2.2K | 329,287 | — | ↗ |
| 2007-03-08 | BEESE J CARTER JR | Director | P-Purchase | A | Nastech Pharmaceutical Company Inc Common Stock | 2,000 | 10.75 | 21.5K | 14,500 | — | ↗ |
| 2007-03-01 | WENIG DEVIN | Director | S-Sale | D | Nastech Pharmaceutical Company Inc Common Stock | 100 | 11.09 | 1.1K | 331,187 | — | ↗ |
| 2007-02-27 | QUAY STEVEN C | Director / Officer | S-Sale | D | Nastech Pharmaceutical Company Inc Common Stock | 2,000 | 11.40 | 22.8K | 469,442 | — | ↗ |
| 2007-02-07 | BRANDT GORDON | Officer | M-Exempt | A | Nastech Pharmaceutical Company Inc Common Stock | 1,667 | 10.39 | 17.3K | 28,165 | — | ↗ |
Executive team
Top executives
Shares Outstanding
7.22M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2021 | Andrew Kucharchuk Chief Executive Officer | 186.0K | — | — | — | — | — | 186.0K | 0.00% | ↗ |
| 2 | 2020 | Andrew Kucharchuk Chief Executive Officer | 60.0K | — | — | — | — | — | 60.0K | 0.00% | ↗ |
| 3 | 2018 | Robert C. Moscato, Jr., former CEO and Secretary | 190.7K | 6.9K | — | 219.3K | — | 18.7K | 435.5K | 50.34% | ↗ |
| 4 | 2018 | Vuong Trieu, former Executive Chairman and Interim CEO | 31.8K | — | — | 4.1K | — | 299.4K | 335.4K | 1.23% | ↗ |
| 5 | 2018 | Erik Emerson, Director & former CCO | 106.3K | — | — | 164.5K | — | 26.9K | 297.6K | 55.25% | ↗ |
| 6 | 2018 | Joseph W. Ramelli, former CEO | 40.0K | — | — | 68.8K | — | 85.2K | 194.0K | 35.47% | ↗ |
| 7 | 2018 | Eric Teague, former CFO | 77.2K | — | — | 65.7K | — | 6.9K | 149.8K | 43.87% | ↗ |
| 8 | 2017 | Erik Emerson, Director & Chief Commercial Officer | — | — | 228.0K | — | — | 1.7K | 229.7K | 99.26% | ↗ |
| 9 | 2017 | Erik Emerson, Director & former CCO | — | — | 228.0K | — | — | 1.7K | 229.7K | 99.26% | ↗ |
| 10 | 2017 | Vuong Trieu, Ph.D., Former Executive Chairman and Interim CEO | — | — | — | 11.2K | — | 147.8K | 159.0K | 7.07% | ↗ |
| 11 | 2017 | Vuong Trieu, former Executive Chairman and Interim CEO | — | — | — | 11.2K | — | 147.8K | 159.0K | 7.07% | ↗ |
| 12 | 2017 | Joseph W. Ramelli, former CEO | 107.2K | — | 14.0K | 11.2K | — | 5.9K | 138.3K | 18.25% | ↗ |
| 13 | 2017 | Joseph W. Ramelli, former Chief Executive Officer | 107.2K | — | 14.0K | 11.2K | — | 5.9K | 138.3K | 18.25% | ↗ |
| 14 | 2016 | J. Michael French, former President, CEO & and Director of Marina Biotech | 169.9K | — | — | — | — | 5.3K | 175.2K | 0.00% | ↗ |
| 15 | 2016 | Joseph W. Ramelli, former Chief Executive Officer | 82.5K | — | — | 11.4K | — | — | 93.9K | 12.19% | ↗ |
| 16 | 2016 | Joseph W. Ramelli CEO and former director | 82.5K | — | — | 11.4K | — | — | 93.9K | 12.19% | ↗ |
| 17 | 2015 | J. Michael French, former President, CEO & and Director of Marina Biotech | 425.0K | — | — | — | — | — | 425.0K | 0.00% | ↗ |
| 18 | 2014 | J. Michael French, President, CEO and Director | 288.1K | — | — | 774.9K | — | — | 1.06M | 72.90% | ↗ |
| 19 | 2014 | Daniel E. Geffken, Interim CFO | — | — | — | — | — | 136.4K | 136.4K | 0.00% | ↗ |
| 20 | 2013 | J. Michael French, President, CEO and Director | 127.5K | — | — | — | — | — | 127.5K | 0.00% | ↗ |
| 21 | 2013 | Philip C. Ranker, Interim CFO and Secretary | 103.1K | — | — | — | — | — | 103.1K | 0.00% | ↗ |
| 22 | 2012 | J. Michael French, President, CEO and Director | 141.5K | — | — | — | — | — | 141.5K | 0.00% | ↗ |
| 23 | 2012 | Philip C. Ranker, Interim CFO and Secretary | 135.3K | — | — | — | — | — | 135.3K | 0.00% | ↗ |
| 24 | 2012 | Richard T. Ho, M.D., Ph.D., EVP – R&D | 102.4K | — | — | — | — | — | 102.4K | 0.00% | ↗ |
| 25 | 2010 | J. Michael French, President, CEO and Director | 340.0K | — | — | 163.1K | — | — | 503.1K | 32.42% | ↗ |
| 26 | 2010 | Peter S. Garcia, CFO and Secretary | 310.0K | — | — | 46.0K | — | 45.0K | 401.0K | 11.48% | ↗ |
| 27 | 2010 | Barry Polisky, Ph.D., Chief Scientific Officer | 306.2K | — | — | — | — | — | 306.2K | 0.00% | ↗ |
| 28 | 2009 | J. Michael French, President, CEO and Director | 340.0K | — | — | 298.8K | — | 102.0K | 740.8K | 40.34% | ↗ |
| 29 | 2009 | Barry Polisky, Ph.D., Chief Scientific Officer | 375.0K | — | — | 228.0K | — | 25.0K | 628.0K | 36.31% | ↗ |
| 30 | 2009 | Peter S. Garcia, CFO and Secretary | 141.0K | — | — | 416.3K | — | 45.0K | 602.2K | 69.12% | ↗ |
| 31 | 2008 | Steven C. Quay, Director (Former Chairman, CEO and CSO) | 511.2K | — | 959.3K | 3.90M | — | 3.8K | 5.38M | 90.42% | ↗ |
| 32 | 2008 | Timothy M. Duffy, Former CBO | 209.2K | — | 257.3K | 230.4K | — | 252.3K | 949.2K | 51.38% | ↗ |
| 33 | 2008 | Gordon C. Brandt, Former President | 318.8K | — | 217.5K | 197.9K | — | 96.4K | 830.5K | 50.01% | ↗ |
| 34 | 2008 | J. Michael French, President, CEO and Director | 176.3K | — | — | 296.1K | — | — | 472.4K | 62.68% | ↗ |
| 35 | 2008 | Bruce R. York, CFO and Secretary | 224.2K | — | 42.3K | 98.0K | — | 3.7K | 368.2K | 38.11% | ↗ |
| 36 | 2007 | Dr. Steven C. Quay, Chairman and CEO | 525.0K | — | 617.6K | 1.56M | — | 5.1K | 2.70M | 80.40% | ↗ |
| 37 | 2007 | Steven C. Quay, Director (Former Chairman, CEO and CSO) | 525.0K | — | 617.6K | 1.56M | — | 5.1K | 2.70M | 80.40% | ↗ |
| 38 | 2007 | Philip C. Ranker, Former CFO | 250.0K | — | 190.0K | 145.7K | — | 3.8K | 589.4K | 56.95% | ↗ |
| 39 | 2007 | Timothy M. Duffy, Former CBO | 249.5K | — | 183.5K | 148.4K | — | 3.7K | 585.1K | 56.72% | ↗ |
| 40 | 2007 | Timothy M. Duffy, EVP, Business Development & Marketing | 249.5K | — | 183.5K | 148.4K | — | 3.7K | 585.1K | 56.72% | ↗ |
| 41 | 2007 | Dr. Gordon C. Brandt, President | 287.0K | — | 112.2K | 101.3K | — | 3.9K | 504.4K | 42.33% | ↗ |
| 42 | 2007 | Gordon C. Brandt, Former President | 287.0K | — | 112.2K | 101.3K | — | 3.9K | 504.4K | 42.33% | ↗ |
| 43 | 2007 | David E. Wormuth, Former SVP, Operations | 262.3K | — | 105.6K | 110.6K | — | 2.9K | 481.4K | 44.90% | ↗ |
| 44 | 2007 | Peter J. Knudsen Intellectual Property Counsel | 235.0K | — | 57.5K | — | 16.2K | — | 308.7K | 18.62% | ↗ |
| 45 | 2007 | Bruce R. York, CFO and Secretary | 183.7K | — | 46.8K | — | 18.3K | 2.8K | 251.5K | 18.59% | ↗ |
| 46 | 2006 | Steven C. Quay, Director (Former Chairman, CEO and CSO) | 500.0K | — | 617.6K | 1.58M | 214.5K | 3.6K | 2.92M | 75.39% | ↗ |
| 47 | 2006 | Dr. Steven C. Quay, Chairman, President and CEO (Principal Executive Officer) | 500.0K | — | 617.6K | 1.58M | 214.5K | 3.6K | 2.92M | 75.39% | ↗ |
| 48 | 2006 | Dr. Steven C. Quay, Chairman and CEO | 500.0K | — | 617.6K | 1.58M | 214.5K | 3.6K | 2.92M | 75.39% | ↗ |
| 49 | 2006 | Philip C. Ranker, CFO, (Principal Financial Officer) | 230.0K | — | 158.6K | 125.3K | 84.5K | 3.5K | 601.9K | 47.18% | ↗ |
| 50 | 2006 | Philip C. Ranker, Former CFO | 230.0K | — | 158.6K | 125.3K | 84.5K | 3.5K | 601.9K | 47.18% | ↗ |
| 51 | 2006 | Timothy M. Duffy, EVP, Business Development & Marketing | 238.1K | — | 159.5K | 100.8K | 84.5K | 3.6K | 586.5K | 44.38% | ↗ |
| 52 | 2006 | Timothy M. Duffy, EVP Business Dev, Marketing & Legal | 238.1K | — | 159.5K | 100.8K | 84.5K | 3.6K | 586.5K | 44.38% | ↗ |
| 53 | 2006 | Timothy M. Duffy, Former CBO | 238.1K | — | 159.5K | 100.8K | 84.5K | 3.6K | 586.5K | 44.38% | ↗ |
| 54 | 2006 | Dr. Paul H. Johnson, SVP R&D and Chief Scientific Officer | 239.2K | — | 50.8K | 182.7K | 74.7K | 3.0K | 550.3K | 42.42% | ↗ |
| 55 | 2006 | Dr. Gordon C. Brandt, EVP Clinical Research and Medical Affairs | 275.0K | — | 64.2K | 107.5K | 89.1K | 3.3K | 539.0K | 31.85% | ↗ |
| 56 | 2006 | Dr. Gordon C. Brandt, President | 275.0K | — | 64.2K | 107.5K | 89.1K | 3.3K | 539.0K | 31.85% | ↗ |
| 57 | 2006 | Gordon C. Brandt, Former President | 275.0K | — | 64.2K | 107.5K | 89.1K | 3.3K | 539.0K | 31.85% | ↗ |
| 58 | 2006 | David E. Wormuth, Former SVP, Operations | 263.1K | — | 28.8K | 130.4K | 99.3K | 3.7K | 525.2K | 30.31% | ↗ |
| 59 | 2006 | Peter J. Knudsen Intellectual Property Counsel | 186.3K | — | 41.7K | — | 18.6K | — | 246.6K | 16.90% | ↗ |
| 60 | 2006 | Bruce R. York, CFO and Secretary | 176.0K | — | 49.7K | — | 17.6K | 2.6K | 245.9K | 20.22% | ↗ |
| 61 | 2005 | Dr. Steven C. Quay Chairman, President and Chief Executive Officer | 432.6K | 200.0K | 2.47M | 600.0K | — | — | 3.70M | 82.92% | ↗ |
| 62 | 2005 | Dr. Gordon C. Brandt Executive Vice President Clinical Research and Medical Affairs | 253.0K | 88.6K | 192.7K | 15.0K | — | — | 549.2K | 37.81% | ↗ |
| 63 | 2005 | Dr. Paul H. Johnson Senior Vice President, Research and Development and Chief Scientific Officer | 230.0K | 78.5K | 152.4K | 11.5K | — | — | 472.4K | 34.70% | ↗ |
| 64 | 2005 | David E. Wormuth Senior Vice President, Operations | 235.0K | 79.0K | 86.5K | 7.5K | — | — | 408.0K | 23.04% | ↗ |
| 65 | 2005 | Philip C. Ranker Chief Financial Officer | 201.6K | 47.8K | 42.4K | — | — | — | 291.8K | 14.53% | ↗ |
| 66 | 2004 | Dr. Steven C. Quay Chairman, President and Chief Executive Officer | 393.3K | 200.0K | — | — | — | — | 593.3K | 0.00% | ↗ |
| 67 | 2004 | Gregory L. Weaver Chief Financial Officer | 250.0K | 100.0K | 84.3K | 7.5K | — | — | 441.8K | 20.78% | ↗ |
| 68 | 2004 | David E. Wormuth Senior Vice President, Operations | 228.3K | 74.9K | — | 25.0K | — | — | 328.1K | 7.62% | ↗ |
| 69 | 2004 | Dr. Paul H. Johnson Senior Vice President, Research and Development and Chief Scientific Officer | 249.8K | 56.3K | — | — | — | — | 306.1K | 0.00% | ↗ |
| 70 | 2004 | Dr. Gordon C. Brandt Executive Vice President Clinical Research and Medical | 224.8K | 73.8K | — | — | — | — | 298.6K | 0.00% | ↗ |
| 71 | 2004 | Dr. Gordon C. Brandt Executive Vice President Clinical Research and Medical Affairs | 224.8K | 73.8K | — | — | — | — | 298.6K | 0.00% | ↗ |
| 72 | 2004 | Philip C. Ranker Chief Financial Officer | 65.2K | 9.7K | 138.4K | 15.0K | — | — | 228.3K | 67.17% | ↗ |
| 73 | 2003 | Dr. Steven C. Quay Chairman, President and Chief Executive Officer | 357.5K | 50.0K | — | — | — | — | 407.5K | 0.00% | ↗ |
| 74 | 2003 | Dr. Steven C. Quay President, Chairman and Chief Executive Officer | 357.5K | 50.0K | — | — | — | — | 407.5K | 0.00% | ↗ |
| 75 | 2003 | Gregory L. Weaver Chief Financial Officer | 242.8K | 97.1K | — | 25.0K | — | — | 364.9K | 6.85% | ↗ |
| 76 | 2003 | David E. Wormuth Senior Vice President, Operations | 207.4K | 83.0K | — | 25.0K | — | — | 315.4K | 7.93% | ↗ |
| 77 | 2003 | Dr. Gordon C. Brandt Executive Vice President Clinical Research and Medical Affairs | 200.0K | 80.3K | — | 25.0K | — | — | 305.3K | 8.19% | ↗ |
| 78 | 2003 | Dr. Gordon C. Brandt Executive Vice President Clinical Research and Medical | 200.0K | 80.3K | — | 25.0K | — | — | 305.3K | 8.19% | ↗ |
| 79 | 2003 | Dr. Paul H. Johnson Senior Vice President, Research and Development and Chief Scientific Officer | 51.5K | 22.0K | — | 90.0K | — | — | 163.5K | 55.03% | ↗ |
| 80 | 2002 | Dr. Steven C. Quay President and Chief Executive Officer | 316.9K | 25.0K | — | 900.0K | — | — | 1.24M | 72.47% | ↗ |
| 81 | 2002 | Dr. Steven C. Quay Chairman, President and Chief Executive Officer | 316.9K | 25.0K | — | 900.0K | — | — | 1.24M | 72.47% | ↗ |
| 82 | 2002 | Dr. Steven C. Quay President, Chairman and Chief Executive Officer | 316.9K | 25.0K | — | 900.0K | — | — | 1.24M | 72.47% | ↗ |
| 83 | 2002 | Mr. Gregory Weaver Chief Financial Officer | 146.1K | 47.8K | — | 125.0K | — | 100.0K | 418.9K | 29.84% | ↗ |
| 84 | 2002 | Gregory L. Weaver Chief Financial Officer | 146.1K | 47.8K | — | 125.0K | — | 100.0K | 418.9K | 29.84% | ↗ |
| 85 | 2002 | Mr. David Wormuth Senior Vice President, Operations | 192.5K | 79.1K | — | 10.0K | — | 29.6K | 311.1K | 3.21% | ↗ |
| 86 | 2002 | David E. Wormuth Senior Vice President, Operations | 192.5K | 79.1K | — | 10.0K | — | — | 281.5K | 3.55% | ↗ |
| 87 | 2002 | Mr. Dilip Worah Chief Science Officer | 170.0K | 51.0K | — | — | — | 32.6K | 253.6K | 0.00% | ↗ |
| 88 | 2002 | Dr. Gordon C. Brandt Executive Vice President Clinical Research and Medical | 20.5K | 56.7K | — | 90.0K | — | — | 167.2K | 53.84% | ↗ |
| 89 | 2002 | Dr. Gordon C. Brandt Executive Vice President Clinical Research and Medical Affairs | 20.5K | 56.7K | — | 90.0K | — | — | 167.2K | 53.84% | ↗ |
| 90 | 2001 | Dr. Steven C. Quay President and Chief Executive Officer | 300.0K | 41.2K | — | — | — | 113.4K | 454.6K | 0.00% | ↗ |
| 91 | 2001 | Dr. Steven C. Quay President, Chairman and Chief Executive Officer | 300.0K | 41.2K | — | — | — | 113.4K | 454.6K | 0.00% | ↗ |
| 92 | 2001 | Mr. David Wormuth Senior Vice President, Operations | 141.4K | 36.6K | — | 80.0K | — | 45.0K | 303.0K | 26.40% | ↗ |
| 93 | 2001 | David E. Wormuth Senior Vice President, Operations | 141.4K | 36.6K | — | 80.0K | — | 45.0K | 303.0K | 26.40% | ↗ |
| 94 | 2001 | Mr. Dilip Worah Chief Science Officer | 72.5K | — | — | 80.0K | — | 38.9K | 191.3K | 41.81% | ↗ |
| 95 | 2000 | Dr. Steven C. Quay President and Chief Executive Officer | 121.0K | 15.0K | — | 600.0K | — | — | 736.0K | 81.52% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Andrew Albert Kucharchuk | Vice Chairman, Chief Operating Officer & Chief Business Officer | 285.0K | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ATRX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
